AI Insight
This study examined the Netrin-1 signaling pathway in glioblastoma (GBM) by analyzing single-cell RNA sequencing data from over 148,000 cells and bulk RNA sequencing survival data from 480 patients across three independent cohorts. The gene NTN1 was identified as a consistent risk factor associated with worse survival (Meta HR=1.163, p=0.0021), while DCC and RGMB showed trends toward better outcomes. An exploratory sex-stratified analysis suggested that NEO1 and NTN1 may carry heightened prognostic risk specifically in female patients, though this finding requires further validation.
Why it matters
Identifying NTN1 as a candidate therapeutic target in GBM could inform the development of more targeted treatments for a cancer with very limited survival options. The potential sex-specific differences in pathway activity, if confirmed, could eventually contribute to more personalized treatment strategies.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: The Netrin-1 dependence receptor pathway plays critical roles in neural development, but its expression landscape and prognostic significance in glioblastoma (GBM) remain poorly characterized. Methods: Single-cell RNA-seq data from 148,019 cells across 34 tumors (Neftel et al., 2019) were analyzed to map Netrin-1 pathway gene expression across GBM cellular states. Bulk RNA-seq survival analysis was conducted across three independent GBM cohorts totaling 480 patients. Primary analysis used continuous Cox regression with fixed-effects meta-analysis. Results: NTN1 emerged as a consistent risk factor (Meta HR=1.163, p=0.0021). DCC and RGMB showed protective trends. Exploratory sex-stratified analysis revealed female-specific risk enhancement for NEO1 and NTN1. Conclusions: The Netrin-1 pathway exhibits divergent prognostic trends in GBM, nominating NTN1 as a candidate therapeutic target.